If you are still thinking about trying to boycott Israel, you might want to think again!
For all the Israel-haters out there, they’d better hope that that Israelis are forgiving if they are stricken with cancer, because if a new report out of Israel turns out to be true, scientists in the Jewish state have discovered a cure. And not just a cure for certain forms of cancer, but a complete cure for the deadly disease.
According to Dan Aridor, chairman of the board of Accelerated Evolution Biotechnologies Ltd. (AEBi) and CEO Dr. Ilan Morad, their treatment will not need time for the body to acculturate to it before it works. Aridor stated, “We believe we will offer in a year’s time a complete cure for cancer. … Our cancer cure will be effective from day one … and will have no or minimal side-effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.”
As the Jerusalem Post reports, “An estimated 18.1 million new cancer cases are diagnosed worldwide each year, according to reports by the International Agency for Research on Cancer. Further, every sixth death in the world is due to cancer, making it the second leading cause of death (second only to cardiovascular disease).”
The treatment is called MuTaTo (multi-target toxin), and works much like antibiotics do in targeting bacteria. MuTaTo is based on SoAP technology, which works by finding, binding and removing bacteria by utilizing bacteriophage-derived proteins. Bacteriophages are viruses that infect bacteria.
MuTaTo inserts DNA coding for a protein into a bacteriophage. Once inside, the protein shows up on the phage’s surface, making it apparent to researchers who can use the phages to find interactions with other proteins, DNA sequences and small molecules. Unlike 2018 Nobel Prize-winning scientists George Smith and Gregory Winter, who used phage display to evolve new proteins or antibodies, the Israelis are producing peptides, which Morad says are better equipped for the job because they are smaller, less expensive and less difficult to manage.
Morad said the company’s initial efforts involved attempting to find “individual novel peptides for specific cancers.” But then he and colleague Dr. Hanan Itzhaki decided to go for broke. He explained that most anti-cancer drugs attack a specific target on or in the cancer cell, but they often trigger a mutation that makes the drug ineffective. But MuTato, as the Jerusalem Post notes, uses “a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically.”
Morad said that the company’s technique “made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer … The probability of having multiple mutations that would modify all targeted receptors simultaneously decreases dramatically with the number of targets used. Instead of attacking receptors one at a time, we attack receptors three at a time – not even cancer can mutate three receptors at the same time.”
Morad said MuTato, because it attacks multiple targets, destroys the proteins targeted on the cancer cell. Morad also said because the peptide parts of MuTaTo are tiny and flexible, they can penetrate areas other drugs fail to reach. He stated, “This should make the whole molecule non-immunogenic in most cases and would enable repeated administration of the drug.”
Morad said the treatment could reduce side effects , which often arise because cancer treatments either connect with the wrong or additional targets, or the right targets on healthy cells. Aridor concluded, “Our results are consistent and repeatable.”